Ulisse Biomed Spa
MIL:UBM

Watchlist Manager
Ulisse Biomed Spa Logo
Ulisse Biomed Spa
MIL:UBM
Watchlist
Price: 0.766 EUR -1.03% Market Closed
Market Cap: 16.9m EUR
Have any thoughts about
Ulisse Biomed Spa?
Write Note

Ulisse Biomed Spa
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ulisse Biomed Spa
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Ulisse Biomed Spa
MIL:UBM
Total Current Liabilities
€1.2m
CAGR 3-Years
57%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Genenta Science SPA
NASDAQ:GNTA
Total Current Liabilities
€1.7m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Philogen SpA
MIL:PHIL
Total Current Liabilities
€12.7m
CAGR 3-Years
0%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
No Stocks Found

Ulisse Biomed Spa
Glance View

Market Cap
16.7m EUR
Industry
Biotechnology

Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.

UBM Intrinsic Value
0.641 EUR
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Ulisse Biomed Spa's Total Current Liabilities?
Total Current Liabilities
1.2m EUR

Based on the financial report for Dec 31, 2023, Ulisse Biomed Spa's Total Current Liabilities amounts to 1.2m EUR.

What is Ulisse Biomed Spa's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
42%

Over the last year, the Total Current Liabilities growth was 268%. The average annual Total Current Liabilities growth rates for Ulisse Biomed Spa have been 57% over the past three years , 42% over the past five years .

Back to Top